Compare Adecoagro SA (AGRO) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adecoagro SA vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Adecoagro SA trades at $9.47 (market cap $1.39B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 6.8× Adecoagro SA's market cap, and Adecoagro SA pays a 3.07% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| AGRO | BIO | |
|---|---|---|
Market Cap | $1.39B | $9.39B |
Sector | Technology | Health |
52-Week High | $15.25 | $356.25 |
52-Week Low | $7.13 | $241.71 |
Enterprise Value | $3.43B | $9.14B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGRO trades at $9.45, up 0.96% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported negative net income of -$8.35M for 2025 despite $1.43B revenue, though 2026 projections show potential profitability improvement. Recent acquisition of Caarapó Mill expands operational footprint while analyst consensus leans neutral with 50% hold ratings.
Outlook remains cautious with elevated P/E ratio of 536.67 offset by attractive P/B of 0.79. Key risks include commodity volatility and integration challenges from recent acquisitions. The stock presents value opportunity if 2026 profitability targets are achieved, but requires careful monitoring of earnings trajectory.
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adecoagro SA
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
